Slow-acting antirheumatic drugs. Drug interactions of clinical significance.
The slow-acting antirheumatic drugs (SAARDs) are being used in an increasing proportion of patients with rheumatoid arthritis (RA). The potential toxicity of each drug is well recognised. Many patients with RA will be on other medications and the potential for adverse drug interactions with SAARDs is not so well publicised. There have, over the years, been numerous reports of possible drug interactions with SAARDs but few of these are clinically relevant. It is, however, vitally important that the physician is aware of a number of potentially life-threatening interactions, particularly those associated with methotrexate. The SAARDs are a very useful group of drugs for the treatment of RA and, by being aware of their potential toxicity and drug interactions, hopefully they can be used safely and effectively.
Munro
R A
RA
University Department of Medicine, Glasgow Royal Infirmary University NHS Trust, Scotland.
Sturrock
R D
RD
D018501:Antirheumatic Agents / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004347:Drug Interactions; D006046:Gold / Q000494:pharmacology; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D010396:Penicillamine / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology
D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D006046:Gold; D010396:Penicillamine